Cite
HARVARD Citation
Cohen, J. et al. (n.d.). Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet neurology. 15 (4), pp. 373-381. [Online].